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of proteins, non-enzymatic glycation is one of the 
less frequently studied in proteomics. Glycated pro-
teins are formed by a non-enzymatic reaction bet-
ween reducing carbohydrates (e.g., glucose, fructo-
se, ribose or derivatives such as ascorbic acid) with 
amino groups located in N-terminal position or in ly-
sine and arginine residues (Figure 1) [1]. Analytical 
guidelines required to succeed in the characterization 
of glycated proteins at qualitative levels have been 
UHFHQWO\SURSRVHG>@,WLQYROYHVWKHLGHQWL¿FDWLRQ
of glycated proteins as well as the elucidation of su-
gar attachment sites. Nevertheless, there is a demand 
for quantitative proteomic strategies that could be 
potentially applied for glycation assessment. One of 
WKHDUHDVWKDWFRXOGEHQH¿WIURPWKHVHVWUDWHJLHVLV
WKHFOLQLFDO¿HOGGXHWRWKHFUXFLDOUROHRIJOXFRVHDV
an energy source in humans, being the main circu-
lating sugar and, thus, the most relevant molecule in 
terms of protein glycation. In fact, there are clinical 
evidences relating glycation and pathological condi-
tions associated to hyperglycaemia such as diabetes 
mellitus, renal failure or aging [5-7].
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A set of innovative approaches for analysis of 
glycated proteins is here presented by application to 
blood samples [8]. Qualitative analysis was carried 
out by tandem mass spectrometry (MS) after en-
GRSURWHLQDVH*OX&GLJHVWLRQDQGERURQDWHDI¿QLW\
chromatography (BAC) for isolation of glycated pep-
tides. For this purpose, two MS operational modes 
were used: HCD-MS2 and CID-MS3 by neutral loss 
scan (monitoring two selective neutral losses typical 
RISHSWLGHVPRGL¿HGE\JOXFRVHDWWDFKPHQW
and 84.04 Da). Quantitative analysis was based on the 
labelling of proteins with 13C
6
-glucose incubation in 
order to evaluate the native glycated proteins labelled 
with 12C
6
-glucose. As glycation is chemo-selective, it 
is exclusively occurring in potential targets for in vivo 
PRGL¿FDWLRQV7KLVDSSURDFKQDPHG*O\FDWLRQ,VRWR-
pic Labelling (GIL), enabled to differentiate glycated 
peptides labelled with both isotopic forms resulting 
from enzymatic digestion by MS (6 Da mass shift per 
glycation site) as shown in Figure 2.
:LWK WZRGLIIHUHQW SXUSRVHV WKLV VWUDWHJ\KDV
been applied to human plasma and lysates from 
Figure 1. Scheme of the glycation process (Maillard reaction).
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Figure 2. %RWWRPXSSURWHRPLFVZRUNÀRZVXVHGIRUTXDQWLWDWLYHDQDO\VLVRIJO\FDWHGSURWHLQVVKRZLQJWKHODEHOOLQJZLWK
light and heavy glucose.
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HU\WKURF\WHV7KH¿UVWRQHZDVEDVHGRQWKHFKDUDF-
terization of the native glycated proteome, incuba-
ting the clinical samples with 13C
6
-glucose prior to 
DQDO\VLVZLWKWKHFRQYHQWLRQDOSURWHRPLFVZRUNÀRZ
exposed above. Fifty glycated proteins with identi-
¿FDWLRQRIVXJDUDWWDFKPHQWSRVLWLRQVZHUHGH-
tected in the analysis of human plasma. Concerning 
UHGEORRGFHOOVJO\FDWHGSURWHLQVZLWKLGHQWL¿FD-
tion of 54 glycation sites were detected without any 
protein pre-fractionation step. These proteins are 
representative targets to compare between samples 
with different glycaemic states and monitor the gly-
caemic control. The second task was focused on the 
assessment of glucose stimuli at different concen-
trations (0, 5, 10, 30 and 50 mM glucose) in human 
SODVPD)RUWKLVSXUSRVH¿YHSODVPDDOLTXRWVZHUH
independently incubated with 0, 5, 10, 30 and 50mM 
12C
6
-glucose for 24 h and, subsequently mixed with 
a plasma aliquot incubated with 30mM 13C
6
-glucose 
for 24 h. Proteomic analysis of these pools has re-
vealed additional information about the biological 
effect of different hyperglycemia conditions and the 
kinetic of glycation.
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